Compare Firy Inc. (FIRY) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Summit Therapeutics Inc — how do they compare? Firy Inc. trades at $9.81 (market cap $159.51M), while Summit Therapeutics Inc trades at $15.29 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 75.6× Firy Inc.'s market cap, and Firy Inc. is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| FIRY | SMMT | |
|---|---|---|
Market Cap | $159.51M | $12.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $12.45 | $26.98 |
52-Week Low | $2.28 | $12.55 |
Enterprise Value | $103.18M | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY trades at $10.48, up 0.29% today, with a bullish technical outlook from moving averages. The company shows improving revenue trends ($104.5M in 2025) but continues to report significant losses (-$70.41M net income). Recent developments include a $719 million legal victory and corporate rebranding from Skillz Inc. Analyst sentiment remains mixed with a 60% hold rating.
The stock presents speculative potential from legal wins and revenue stabilization, but persistent negative margins and cash burn (-$86.41M net cash flow) pose substantial risks. Upside depends on achieving profitability, while downside risk remains elevated from ongoing operational losses.
Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.
The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
